Kenneth S Koblan Selected Research

SEP-363856

3/2024	TAAR1 agonist ulotaront delays gastric emptying of solids in patients with schizophrenia and concurrent metabolic syndrome with prediabetes.
1/2024	TAAR1 Agonists Improve Glycemic Control, Reduce Body Weight and Modulate Neurocircuits Governing Energy Balance and Feeding.
12/2023	TAAR1 agonist ulotaront modulates striatal and hippocampal glutamate function in a state-dependent manner.
10/2023	A Novel Method for Deriving Adverse Event Prevalence in Randomized Controlled Trials: Potential for Improved Understanding of Benefit-Risk Ratio and Application to Drug Labels.
8/2023	Effects of ulotaront on brain circuits of reward, working memory, and emotion processing in healthy volunteers with high or low schizotypy.
8/2023	Ulotaront, a Trace Amine-Associated Receptor 1/Serotonin 5-HT1A Agonist, in Patients With Parkinson Disease Psychosis: A Pilot Study.
6/2023	Comparative Bioequivalence of Tablet and Capsule Formulations of Ulotaront and the Effect of Food on the Pharmacokinetics of the Tablet Form in Humans.
1/2023	A multicenter, double-blind, placebo-controlled, randomized, Phase 1b crossover trial comparing two doses of ulotaront with placebo in the treatment of narcolepsy-cataplexy.
1/2023	Treatment with the novel TAAR1 agonist ulotaront is associated with reductions in quantitative polysomnographic REM sleep without atonia in healthy human subjects: Results of a post-hoc analysis.
5/2022	In Vitro ADME and Preclinical Pharmacokinetics of Ulotaront, a TAAR1/5-HT1A Receptor Agonist for the Treatment of Schizophrenia.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kenneth S Koblan Research Topics

Disease

23	Schizophrenia (Dementia Praecox) 03/2024 - 11/2010
7	Migraine Disorders (Migraine) 11/2009 - 01/2002
6	Sleep Initiation and Maintenance Disorders (Insomnia) 01/2020 - 07/2009
5	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2021 - 11/2015
4	Body Weight (Weight, Body) 01/2024 - 06/2009
4	Parkinson Disease (Parkinson's Disease) 08/2023 - 10/2008
4	Psychotic Disorders (Schizoaffective Disorder) 08/2023 - 01/2019
3	Bipolar Disorder (Manic Depressive Psychosis) 12/2022 - 01/2021
3	Pain (Aches) 11/2010 - 02/2003
3	Hyperalgesia 07/2007 - 02/2003
2	Binge-Eating Disorder (Binge Eating Disorder) 04/2024 - 01/2020
2	Metabolic Syndrome (Dysmetabolic Syndrome X) 03/2024 - 01/2024
2	Weight Gain 01/2024 - 06/2009
2	Obesity 01/2024 - 06/2009
2	Cognitive Dysfunction 08/2023 - 08/2023
2	Sleepiness 01/2023 - 01/2020
2	Alzheimer Disease (Alzheimer's Disease) 12/2022 - 11/2006
2	Major Depressive Disorder (Major Depressive Disorders) 10/2016 - 08/2013
2	Neuralgia (Stump Neuralgia) 07/2011 - 08/2002
1	Prediabetic State (Prediabetes) 03/2024
1	Nausea 08/2023
1	Hallucinations (Hallucination) 08/2023
1	Dizziness (Lightheadedness) 08/2023
1	Disorders of Excessive Somnolence (Hypersomnia) 08/2023
1	Confusion (Bewilderment) 08/2023
1	Cataplexy 01/2023
1	Narcolepsy 01/2023
1	Autistic Disorder (Autism) 12/2022
1	Substance-Related Disorders (Drug Abuse) 01/2022
1	Mood Disorders (Mood Disorder) 01/2021
1	Headache (Headaches) 01/2020
1	Bulimia (Binge Eating) 01/2020
1	Cardiac Sudden Death (Sudden Cardiac Arrest) 01/2020
1	Neurobehavioral Manifestations 10/2019
1	Epilepsy (Aura) 11/2010
1	Nervous System Diseases (Neurological Disorders) 11/2010
1	Hyperemia 11/2009
1	Coronary Artery Disease (Coronary Atherosclerosis) 11/2009
1	Myocardial Infarction 11/2009
1	Atrial Fibrillation 01/2009
1	Cardiac Arrhythmias (Arrythmia) 01/2009
1	Absence Epilepsy (Childhood Absence Epilepsy) 10/2008
1	Seizures (Absence Seizure) 10/2008
1	Essential Tremor (Essential Tremors) 10/2008

Drug/Important Bio-Agent (IBA)

18	SEP-363856IBA 03/2024 - 10/2019
14	Trace amine-associated receptor 1IBA 03/2024 - 01/2020
9	Antipsychotic Agents (Antipsychotics)IBA 03/2024 - 01/2018
8	Serotonin (5 Hydroxytryptamine)IBA 08/2023 - 11/2009
7	4- (3,4- dichlorophenyl)- 1,2,3,4- tetrahydronaphthalen- 1- amineIBA 04/2024 - 11/2015
7	5-HT1A Serotonin ReceptorIBA 08/2023 - 10/2016
6	Calcitonin Gene-Related Peptide Receptor AntagonistsIBA 02/2008 - 01/2002
5	Calcitonin Gene-Related PeptideIBA 02/2008 - 01/2002
4	Serotonin 5-HT1 Receptor AgonistsIBA 08/2023 - 10/2021
3	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 10/2023 - 10/2019
3	CarrageenanIBA 07/2007 - 02/2003
2	Venlafaxine Hydrochloride (Effexor)FDA LinkGeneric 04/2024 - 08/2013
2	Triglycerides (Triacylglycerol)IBA 01/2024 - 12/2021
2	Lurasidone Hydrochloride FDA Link 10/2023 - 01/2018
2	Dopamine (Intropin)FDA LinkGeneric 08/2023 - 02/2016
2	Amisulpride (Solian)IBA 01/2022 - 01/2021
2	T-Type Calcium Channels (T-Type Calcium Channel)IBA 11/2010 - 06/2009
2	olcegepantIBA 02/2008 - 01/2002
2	piperidineIBA 02/2008 - 11/2007
1	4- (3- fluoro- 2- methylphenyl)- 4,5- dihydrooxazol- 2- ylamineIBA 01/2024
1	RO5166017IBA 01/2024
1	Olanzapine (Zyprexa)FDA Link 01/2024
1	CorticosteroneIBA 01/2024
1	Glutamic Acid (Glutamate)FDA Link 12/2023
1	Risperidone (Risperdal Consta)FDA LinkGeneric 12/2022
1	ProlactinIBA 12/2021
1	CholesterolIBA 12/2021
1	Capsules (Microcapsules)IBA 10/2021
1	TabletsIBA 10/2021
1	Dopamine Receptors (Dopamine Receptor)IBA 01/2021
1	Antidepressive Agents (Antidepressants)IBA 01/2021
1	Chlorpromazine (Thorazine)FDA Link 10/2019
1	Phencyclidine (Angel Dust)IBA 10/2019
1	3,4-dihydroxyphenylglycolIBA 02/2016
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 02/2016
1	Catechol O-Methyltransferase (Methyltransferase, Catechol)IBA 08/2013
1	Orexin Receptor AntagonistsIBA 01/2010
1	Tryptamines (Triptans)IBA 11/2009
1	Sumatriptan (Imigran)FDA LinkGeneric 11/2009
1	OrexinsIBA 07/2009
1	2- (4- cyclopropylphenyl)- N- (1- (5- ((2,2,2- trifluoroethyl)oxo)pyridin- 2- yl)ethyl)acetamideIBA 06/2009
1	triphenylphosphine oxideIBA 01/2009
1	Voltage-Gated Potassium Channels (Voltage-Gated Potassium Channel)IBA 01/2009
1	compound 30IBA 10/2008
1	telcagepantIBA 02/2008
1	NeuropeptidesIBA 02/2008
1	Amyloid beta-PeptidesIBA 11/2006
1	Proteins (Proteins, Gene)FDA Link 11/2006
1	Peptides (Polypeptides)IBA 11/2006
1	Amyloid (Amyloid Fibrils)IBA 11/2006
1	BenzodiazepinesIBA 10/2006
1	PiperidinesIBA 10/2006

Therapy/Procedure

3	Therapeutics 01/2022 - 02/2008
2	Ligation 07/2011 - 08/2002
1	Glycemic Control 01/2024
1	Oral Administration 07/2011